Digital Remote Management for Care and Continuous Optimization Versus Usual Care to Reduce Risk of Atherosclerotic Cardiovascular Diseases (DigiCare-ASCVD)

NCT ID: NCT07332468

Last Updated: 2026-01-12

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 790 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-31
• Study Completion Date: 2027-04-30

Brief Summary

The DigiCare-ASCVD study is an investigator-initiated, multicenter, open-label, parallel-group randomized controlled trial. It aims to evaluated whether digital remote management is superior to usual care in reducing risk of atherosclerotic cardiovascular diseases and improving blood pressure control, glycemic control, lipids control, medication compliance and lifestyle.

Detailed Description

"Atherosclerotic cardiovascular disease (ASCVD) is a leading global cause of mortality. Primary care is central to its prevention within tiered healthcare systems, yet faces challenges including physician training gaps and inefficient specialist referrals. Digital remote interventions offer a promising solution due to widespread smartphone/internet access, enabling convenient care and real-time data use. Current tools focus on patient education/reminders or clinical decision support (CDSS) separately. However, effective long-term ASCVD management requires an integrated system that combines CDSS-guided treatment with comprehensive, sustained risk-factor monitoring (e.g., blood pressure, lipids). This study aims to develop and validate such an integrated remote management platform to overcome multi-level barriers, disseminate advanced resources to primary care, and enhance equitable cardiovascular risk prevention.

The DigiCare-ASCVD Study is a multicenter, open-label, randomized controlled trial with a 1:1 parallel-group design. It will enroll 790 patients at high risk for ASCVD. All enrolled patients will be randomly assigned in a 1:1 ratio to either the Digital Remote Management group or the usual care group.

Patients in the Digital Remote Management group will utilize a smartphone-based ""physician-machine collaboration"" platform. This system integrates home monitoring to track BP, lipids,glucose, medication compliance and physical activity. It features AI-driven alerts for abnormal values, automated medication adjustment suggestions (verified by physicians), and targeted health education The primary endpoint is the mean change in the patient's 10-year ASCVD risk, calculated using the China-PAR risk prediction model, from baseline to the 12-month follow-up."

Conditions

Atherosclerotic Cardiovascular Diseases

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Usual care Group

Usual Care Group: Patients receive standard BP, lipids,glucose and physical activity management including guideline-directed medication and outpatient follow-up at 3, 6, 9, 12 months.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Digital Remote Management Group

In addition to usual care, patients receive a 1-year intervention via a smartphone-based ""physician-machine collaboration"" platform：

1. BP Management: Daily or weekly self-monitoring based on control status. System triggers alerts for BP >130/80 mmHg and generates medication adjustment suggestions for physician approval.

2. Lipid Management: Reminder for lab tests. OCR technology parses results. If LDL-C ≥2.6 mmol/L, the system suggests regimen intensification for physician review.

3. Blood Glucose Management: Reminder for lab tests. OCR technology parses results.If Fasting Blood Glucose (FBG) ≥6.1 mmol/L for patients without diabetes and FBG ≥7.0 mmol/L for patients with diabetes, the system suggests regimen intensification for physician review.

4. Medication Management: Daily app-based reminders and clock-in tasks. Non-adherence triggers automated reminders and human follow-up.

5. Health Education: Regular push of targeted articles/videos on secondary prevention。

Group Type: EXPERIMENTAL

Digital Remote Management Group

Intervention Type: OTHER

In addition to usual care, patients receive a 1-year intervention via a smartphone-based ""physician-machine collaboration"" platform：

1. BP Management: Daily or weekly self-monitoring based on control status. System triggers alerts for BP >130/80 mmHg and generates medication adjustment suggestions for physician approval.

2. Lipid Management: Reminder for lab tests. OCR technology parses results. If LDL-C ≥2.6 mmol/L, the system suggests regimen intensification for physician review.

3. Blood Glucose Management: Reminder for lab tests. OCR technology parses results.If Fasting Blood Glucose (FBG) ≥6.1 mmol/L for patients without diabetes and FBG ≥7.0 mmol/L for patients with diabetes, the system suggests regimen intensification for physician review.

4. Medication Management: Daily app-based reminders and clock-in tasks. Non-adherence triggers automated reminders and human follow-up.

5. Health Education: Regular push of targeted articles/videos on secondary prevention。

Interventions

Digital Remote Management Group

In addition to usual care, patients receive a 1-year intervention via a smartphone-based ""physician-machine collaboration"" platform：

1. BP Management: Daily or weekly self-monitoring based on control status. System triggers alerts for BP >130/80 mmHg and generates medication adjustment suggestions for physician approval.

2. Lipid Management: Reminder for lab tests. OCR technology parses results. If LDL-C ≥2.6 mmol/L, the system suggests regimen intensification for physician review.

3. Blood Glucose Management: Reminder for lab tests. OCR technology parses results.If Fasting Blood Glucose (FBG) ≥6.1 mmol/L for patients without diabetes and FBG ≥7.0 mmol/L for patients with diabetes, the system suggests regimen intensification for physician review.

4. Medication Management: Daily app-based reminders and clock-in tasks. Non-adherence triggers automated reminders and human follow-up.

5. Health Education: Regular push of targeted articles/videos on secondary prevention。

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. 10-year ASCVD risk ≥ 10%, calculated using the China-PAR risk prediction model

2. Adultd aged ≥ 35 years

3. Able to use a smartphone (or assisted by family) and agrees to remote management

4. Signed informed consent

Exclusion Criteria

1. History of acute myocardial infarction, stroke, heart failure, malignant arrhythmia, or prior percutaneous coronary intervention or coronary artery bypass grafting surgery

2. Moderate to severe hepatic dysfunction (Child-Pugh class B-C)

3. CKD stages 4-5 (eGFR <30 ml/min/1.73m²) or on dialysis

4. Chronic obstructive pulmonary disease requiring ongoing home oxygen therapy or chronic oral steroid therapy as an outpatient

5. Pregnant, planning to become pregnant within the next 12 months

6. Life expectancy <12 months (e.g., advanced malignancy, etc.);

7. Cognitive impairment or communication disorder.

• Minimum Eligible Age: 35 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Beijing Anzhen Hospital

OTHER

Sponsor Role: lead

Responsible Party

Chang sheng Ma

Director of cardiology department

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Beijing Anzhen Hospital, Capital Medical University, Beijing, China

Beijing, , China

The First Hospital of Jilin University, Changchun, China

Changchun, , China

The First Affiliated Hospital of Dalian Medical University, Dalian, China

Dalian, , China

The Second Affiliated Hospital of Nanchang University, Nanchang, China

Nanchang, , China

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Shanghai, , China

Countries

China

Central Contacts

Liu He

Role: CONTACT

theliu@139.com

13810720787

Other Identifiers

KS2025288

Identifier Type: -

Identifier Source: org_study_id